Actionable news
0
All posts from Actionable news
Actionable news in GERN: Geron Corporation,

Geron Corporation

Geron Corp. reports financial results for the quarter ended September 30, 2017.We analyze the earnings along side the following peers of Geron Corp. - Gilead Sciences, Inc., Bio-Techne Corporation and Incyte Corporation (GILD-US, TECH-US and INCY-US) that have also reported for this period.

  • Summary numbers: Revenues of USD 0.16 million, Net Earnings of USD -6.90 million.
  • Year-on-year change in operating cash flow of 32.49% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
  • Narrowing of operating margins contributed to decline in earnings.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2017-09-302017-06-302017-03-312016-12-312016-09-30
Revenues (mil)0.1630.1740.5370.0945.1
Revenue Growth (%YOY)-96.8-17.5-28.3-57.3-85.6
Earnings (mil)-6.9-6.4-7.2-8.5-3.6
Earnings Growth (%YOY)-92.925.818.8-0.165-113.2
Net Margin (%)-4232.5-3681-1337.6-9023.4-70
EPS-0.04-0.04-0.05-0.05-0.02
Return on Equity (%)-6.2-5.6-6-6.8-2.8
Return on Assets (%)-23.1-20.2-22.2-25.5-10.5

Click here to view

Spreadsheet

Spreadsheet

GERN-US's change in revenue this period compared to the same period last year of -96.81% is almost the same as its change in earnings, and is about average among the announced results thus far in its peer group, suggesting that GERN-US is holding onto its market share. Also, for comparison purposes, revenues changed by -6.32% and earnings by -7.71% compared to the immediate last period.SpreadsheetCash Versus Earnings - Sustainable Performance?It is important to examine a company�s cash versus earnings numbers to gauge whether its performance is sustainable.GERN-US's change in operating cash flow of 32.49% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.SpreadsheetThe company's decline in earnings has been influenced by the following factors: (1) Decline in operating margins (EBIT margins) from -75.90% to -4,444.17% and (2) one-time items that contributed to a decrease in pretax margins from -70.01% to -4,232.52%Spreadsheet

Spreadsheet

Spreadsheet

Click here to view

Geron Corp. discovers and develops therapeutic products for cancer. It is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Geron was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of GERN-US.The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party's use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any of our reports, you're agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website www.analytixinsight.com.


More